What is Meghan V. Joyce’s Guardant Health (GH) share ownership after these transactions?

After exercising options and selling shares, Meghan V. Joyce directly holds 11,183 shares of Guardant Health common stock, as reported in the Form 4, with no remaining derivative positions listed in the derivative summary section.

Guardant Health (GH) director exercises options, sells 10,000 shares and holds 11,183

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Guardant Health, Inc. director Meghan V. Joyce reported option exercises and related share sales. On June 3, 2026, she exercised stock options to acquire a total of 10,000 shares of Guardant Health common stock at exercise prices of $38.005 and $38.420 per share.

On the same date, she executed open-market sales totaling 10,000 shares of common stock in multiple price tranches, at weighted average prices reported around the high $120s per share. Following these transactions, she directly holds 11,183 shares of Guardant Health common stock, and the exercised option positions have been fully converted into shares.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($1,269,809)

Net Sell 8 txns

Insider Joyce Meghan V.

Role null

Sold 10,000 shs ($1.27M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	1,197	$0.00	--
Exercise	Stock Option (Right to Buy)	8,803	$0.00	--
Exercise	Common Stock	1,197	$38.42	$46K
Exercise	Common Stock	8,803	$38.005	$335K
Sale	Common Stock	3,516	$126.5157	$445K
Sale	Common Stock	5,728	$127.1054	$728K
Sale	Common Stock	650	$128.0196	$83K
Sale	Common Stock	106	$129.3111	$14K

Holdings After Transaction: Stock Option (Right to Buy) — 7,908 shares (Direct, null); Common Stock — 12,380 shares (Direct, null)

Footnotes (1)

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.785. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $126.815 to $127.75. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $127.92 to $128.24. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.28 to $129.83. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. The stock option award vested in full on June 14, 2023. The stock option award vested in full on June 12, 2024.

Key Figures

Shares sold: 10,000 shares Shares exercised: 10,000 shares Exercise price (primary option): $38.005/share +5 more

8 metrics

Shares sold 10,000 shares Total Guardant Health common shares sold on June 3, 2026

Shares exercised 10,000 shares Total shares acquired via stock option exercises on June 3, 2026

Exercise price (primary option) $38.005/share Stock option covering 8,803 underlying Guardant Health shares

Exercise price (secondary option) $38.420/share Stock option covering 1,197 underlying Guardant Health shares

Shares held after transactions 11,183 shares Direct Guardant Health common stock ownership following June 3, 2026 trades

Sale price example $126.5157/share One reported weighted average sale price tranche on June 3, 2026

Highest reported sale range $129.28–$129.83 Footnote F4 price range for part of the 10,000 shares sold

Option expiration dates 2032-06-14 & 2033-06-14 Expiration for the exercised stock option awards

Key Terms

open-market sale, Stock Option (Right to Buy), weighted average sales price per share, derivative security, +1 more

5 terms

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

underlying security financial

"underlying_security_title: Common Stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/04/2026 - 06:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Joyce Meghan V.

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/03/2026		M		1,197	A	$38.42	12,380	D
Common Stock	06/03/2026		M		8,803	A	$38.005	21,183	D
Common Stock	06/03/2026		S		3,516	D	$126.5157⁽¹⁾	17,667	D
Common Stock	06/03/2026		S		5,728	D	$127.1054⁽²⁾	11,939	D
Common Stock	06/03/2026		S		650	D	$128.0196⁽³⁾	11,289	D
Common Stock	06/03/2026		S		106	D	$129.3111⁽⁴⁾	11,183	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$38.42	06/03/2026		M			1,197	⁽⁵⁾	06/14/2032	Common Stock	1,197	$0	7,908	D
Stock Option (Right to Buy)	$38.005	06/03/2026		M			8,803	⁽⁶⁾	06/14/2033	Common Stock	8,803	$0	0	D

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.785. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $126.815 to $127.75. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $127.92 to $128.24. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.28 to $129.83. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The stock option award vested in full on June 14, 2023.

6. The stock option award vested in full on June 12, 2024.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Meghan Verena Joyce	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Guardant Health (GH) director Meghan V. Joyce report in this Form 4?

Director Meghan V. Joyce reported exercising stock options for 10,000 Guardant Health shares and selling 10,000 shares in open-market transactions on June 3, 2026, leaving her with 11,183 directly held common shares afterward.

How many Guardant Health (GH) shares did Meghan V. Joyce sell and at what prices?

She sold a total of 10,000 Guardant Health common shares in open-market transactions at weighted average prices in the high $120s per share, with detailed ranges from $125.80 up to $129.83 noted in the footnotes.

How many Guardant Health (GH) stock options did Meghan V. Joyce exercise?

She exercised options covering 10,000 Guardant Health shares, split into 8,803 shares at a $38.005 exercise price and 1,197 shares at a $38.420 exercise price, converting these derivative positions into common stock on June 3, 2026.

Were the Guardant Health (GH) stock sales done in a single trade or multiple trades?

The reported sales were executed in multiple transactions. Footnotes explain that each weighted average sale price reflects numerous trades within specified price ranges, and full trade-by-trade details are available from the reporting person upon request.

What do the footnotes say about Meghan V. Joyce’s Guardant Health (GH) option grants?

Footnotes indicate the exercised stock option awards had vested in full by June 14, 2023 and June 12, 2024, meaning the options were fully vested before their June 3, 2026 exercise into Guardant Health common shares.